We Claim:

1. An isolated anti-hFasL human antibody, or antigen-binding portion thereof, comprising at least one polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24.

2. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 1 which comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR).

3. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2 wherein the LCVR comprises a polypeptide with the sequence shown in SEQ ID NO: 2.

4. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2, wherein the LCVR comprises a polypeptide with the sequence shown in SEQ ID NO: 2 and wherein the HCVR comprises a polypeptide with the sequence shown in SEQ ID NO: 10.

5. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2, wherein the LCVR comprises a polypeptide with the sequence shown in SEQ ID NO: 2 and wherein the HCVR comprises a polypeptide with the sequence shown in SEQ ID NO: 18.

6. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the LCVR CDR1 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 4

7. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the LCVR CDR2 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 6.

8. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the LCVR CDR3 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 8.

9. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2, wherein the LCVR CDR1 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 4 and wherein the LCVR CDR2 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 6.

10. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the LCVR CDR1 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 4 and wherein the LCVR CDR3 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 8.

11. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the LCVR CDR2 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 6 and wherein the LCVR CDR3 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 8.

12. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the HCVR CDR1 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 12 or 20.

13. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the HCVR CDR2 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 14 or 22.

14. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the HCVR CDR3 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 16 or 24.

15. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the HCVR CDR2 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 14 or 22 and wherein the HCVR CDR3 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 16 or 24.

16. The isolated anti-hFasL human antibody or antigen-binding portion thereof, of Claim 2, wherein the HCVR CDR1 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 12 or 20 and wherein the HCVR CDR2 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 14 or 22.

17. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2, wherein the HCVR CDR1 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 12 or 20 and wherein the HCVR CDR3 domain comprises a polypeptide with the sequence shown in SEQ ID NO: 16 or 24.

18. The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2, wherein the LCVR comprises a polypeptide with the sequence shown in SEQ ID NO: 2 and wherein the HCVR comprises a polypeptide with the sequence shown in SEQ ID NO:18.

19. The isolated antibody of any one of Claims 1-18 which has an IgG1 heavy chain constant region.

20. The isolated antibody of any one of Claims 1-18 which has an IgG4 heavy chain constant region.

21. The isolated antigen-binding portion of any one of Claims 1-18 which is a Fab fragment.

22. The isolated antigen-binding portion of any one of Claims 1-18 which is a $F(ab')_2$ fragment.

23. The isolated antigen-binding portion of any one of Claims 1-18, which is a single chain Fv fragment.

24. An isolated nucleic acid molecule comprising a polynucleotide encoding an anti-hFasL human antibody, or an antigen-binding portion thereof, of any one of Claims 1-23.

25. A vector comprising the nucleic acid molecule of Claim 24.

26. The vector of Claim 25, wherein the vector is an expression vector.

27. A host cell comprising the vector of Claim 25 or 26.

28. A method for inhibiting hFasL activity comprising contacting hFasL with the antibody or antigen-binding portion thereof of any one of Claims 1-23.

29. A pharmaceutical composition comprising the antibody, or antigen-binding portion thereof, of any one of Claims 1-23 and a pharmaceutically acceptable carrier.

30. A method for inhibiting FasL activity in a subject in need thereof comprising administering to said subject the pharmaceutical composition of Claim 29.

31. A method of treating or preventing a disorder in which FasL activity is detrimental comprising administering to a subject in need thereof the pharmaceutical composition of Claim 29.

32. The method of Claim 31 wherein the disorder is selected from the group consisting of systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute respiratory distress syndrome, severe sepsis, trauma, graft-versus-host disease, organ rejection associated with organ transplant, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute myocardial infarction, cardiomyopathy, cardiac

reperfusion injury, diabetes, cancer, human immunodeficiency virus, influenza virus, hepatic disorders including but not limited to fulminant viral hepatitis B or C, chronic hepatitis C virus, chronic hepatitis B virus, alcoholic hepatitis, hepatic cirrhosis; and renal disorders.

33. Use of the antibody or fragment of any one of Claims 1-23 in the treatment of a disorder to neutralize FasL activity.

34. The use of Claim 33 wherein the disorder is selected from the group consisting of systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute respiratory distress syndrome, severe sepsis, trauma, graft-versus-host disease, organ rejection associated with organ transplant, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute myocardial infarction, cardiomyopathy, cardiac reperfusion injury, diabetes, cancer, human immunodeficiency virus, influenza virus, hepatic disorders including, but not limited to, fulminant viral hepatitis B or C, chronic hepatitis C virus, chronic hepatitis B virus, alcoholic hepatitis, and hepatic cirrhosis; and renal disorders.

35. A human antibody produced by the hybridoma selected from the group consisting of the hybridoma deposited as ATCC PTA-4017 and the hybridoma deposited as ATCC PTA-4018.

36. An isolated human antibody that binds human Fas Ligand and is the antibody 3E1 or antigen-binding portion thereof.

37. An isolated human antibody that binds human Fas Ligand and is the antibody 4G11 or antigen-binding portion thereof.

38. A pharmaceutical composition comprising the isolated human antibody of any one of claims 36 or 37, and a pharmaceutically acceptable carrier.